New hope for lymphoma patients: study tests targeted pill for Tough-to-Treat cancers
NCT ID NCT06068881
First seen Jan 30, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study looked at how well and how safely the drug tazemetostat works in adults with a type of blood cancer called follicular lymphoma that has come back or not responded to previous treatments. Participants took tazemetostat pills twice daily. The study aimed to see if the drug could shrink tumors in patients whose cancers lack a specific genetic change (EZH2 mutation). The study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.